Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (HK:2315) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Biocytogen Pharmaceuticals has announced that IDEAYA Biosciences has exercised an exclusive worldwide license for Biocytogen’s bispecific antibody-drug conjugate, IDE034. This move could bring Biocytogen up to $406.5 million in various payments, as IDEAYA plans to advance IDE034 towards an IND submission to the FDA by 2025.
For further insights into HK:2315 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue